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Abstract
Background: Proton pump inhibitors are often used in critically ill patients to prevent gastrointestinal bleeding despite
limited evidence for benefit. Patients with acute kidney injury requiring renal replacement therapy (RRT) are at high risk of
gastrointestinal bleeding as (pre-)uremia induces coagulopathy through effects on platelets and coagulation cascades. No
high-quality randomized clinical trials have previously assessed the benefits and harms of prophylactic proton pump
inhibitor use in this high-risk population of adult critically ill patients.
Methods/design: Among the 3350 patients included in the Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU)
trial—an investigator-initiated international randomized clinical trial on prophylactic proton pump inhibitor versus placebo
in acutely admitted adult ICU patients at risk of gastrointestinal bleeding—we will compare the benefits and harms of
prophylactic use of proton pump inhibitor in patients in need of RRT versus those not requiring this treatment. We will
determine the proportion of patients with clinically important bleeding, the proportion of patients with adverse events
including pneumonia, Clostridium difficile enteritis, or acute myocardial ischemia in the ICU, as well as transfusion
requirements. Moreover, 90 day and 365 day mortality post-randomization will be investigated. As a secondary analysis,
we will examine the association between acute kidney injury and RRT during ICU stay and gastrointestinal bleeding.
Discussion: With the outlined predefined analysis, we will characterize the balance between the benefits and
harms of stress ulcer prophylaxis in acutely admitted adult ICU patients in need of RRT, including the potential
interaction of allocation to proton pump inhibitor versus placebo.
Trial registration: ClinicalTrials.gov, NCT02718261. Registered on 14 March 2016.
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Background
In a general population of mixed adult intensive care unit
(ICU) patients, overt gastrointestinal bleeding episodes
present in about 5% of cases [1]. Clinically important
gastrointestinal bleeding episodes, which may impact
patient’s morbidity and mortality, occur in about 3% of
cases [1, 2]. In critically ill patients, it is assumed that
bleeding episodes may at least partly result from stress-
induced gastric mucosal damage, and guidelines recom-
mend stress ulcer prophylaxis with proton pump inhibitors
or histamine-2-receptor antagonists [3]. However, the evi-
dence for prophylactic stress ulcer prophylaxis to prevent
gastrointestinal bleeding in critically ill patients is low in
quantity and quality [4].
In the population of ICU patients with RRT-dependent
acute kidney injury, the rate of gastrointestinal bleeding epi-
sodes may be higher, owing to effects of uremia on platelets
and coagulation cascades [5–10]. Moreover, renal replace-
ment therapy (RRT) activates coagulation pathways, owing
to contact with foreign material, and requirement for antic-
oagulation of the extracorporeal circuit may further impair
coagulation [6–15]. Although acute kidney injury is fre-
quently observed in critically ill patients and negatively im-
pacts outcome [5, 12, 16, 17], only a few previous
prospective studies have reported on the incidence and se-
verity of gastrointestinal bleeding in this population. Recent
data from a large randomized clinical trial comparing RRT
modalities in critically ill patients [18] indicated that clinic-
ally relevant all-cause bleeding episodes may be observed in
up to 30% of patients receiving RRT [8, 19]. However, the
trial was conducted in the era prior to the widespread use
of regional RRT anticoagulation (e.g. using citrate), and only
all-cause bleeding was assessed. Accordingly, the collection
of contemporary data and data on gastrointestinal bleeding
in critically ill patients requiring RRT is warranted. More-
over, although the use of prophylactic proton pump
inhibitors in critically ill patients requiring RRT may reduce
the risk of gastrointestinal bleeding, mounting data suggest
an increased risk of serious adverse events, including in-
creased risk of nosocomial infections (e.g. hospital-acquired
pneumonia and Clostridium difficile enteritis) and adverse
cardiovascular events [4, 20].
As for the general ICU population, there are no data
from high-quality randomized clinical trials on the bene-
fits and harms of prophylactic proton pump inhibitors in
RRT-treated critically ill patients. Of note, the use of
proton pump inhibitors in critically ill patients, including
RRT-treated patients, is considered off-label use. Conse-
quently, we aim to assess the balance between the bene-
fits and harms of prophylactic use of proton pump
inhibitors in adult ICU patients with acute kidney injury
requiring RRT. We hypothesize that proton pump in-
hibitor use reduces the risk of gastrointestinal bleeding,
but increases the risk of nosocomial infections.
Objectives
The primary objective of SIREN is to compare the rate of
gastrointestinal bleeding episodes in critically ill patients
with or without need for RRT. Secondary objectives of
SIREN are to balance the benefits and harms of stress
ulcer prophylaxis in this patient population.
Methods
Sup-Icu RENal (SIREN) is a pre-planned sub-analysis
(NCT02718261) of the Stress Ulcer Prophylaxis in the
Intensive Care Unit (SUP-ICU) trial (protocol no. 3.0,
dated 20 October 2015) [21, 22]. This manuscript was
prepared according to the Strengthening the Reporting
of Observational Studies in Epidemiology (STROBE)
statement [23]. A STROBE checklist (Additional file 1)
and a SPIRIT checklist (Additional file 2 and Fig. 1) are
attached.
SUP-ICU trial
The SUP-ICU trial is an investigator-initiated, pragmatic,
international, multicenter, randomized, blinded, parallel-
group trial where 3350 acutely admitted adult ICU
patients with one or more risk factors for gastrointestinal
bleeding are randomized to stress ulcer prophylaxis with
40 mg pantoprazole (Actavis, Gentofte, Denmark) or
placebo intravenously once daily during their ICU stay
(given until ICU discharge or death, for a maximum of
90 days). The SUP-ICU trial medication will be blinded to
the patient, the investigators, the outcome assessors, the
data manager, and the statistician conduction the analysis.
An independent company (NOMECO Clinical Trial
Supply Management, CTSM, Copenhagen, Denmark) will
handle masking, coding, and distribution of trial medica-
tion. Trial site staff will perform computer-based (central)
randomization and trial data will be collected via
electronic case report files. Details of the trial have been
published elsewhere [22]. Some 33 ICUs in six European
countries (Denmark, Norway, Finland, Switzerland, the
Netherlands, and the UK) are randomizing patients [22].
Approvals
The SUP-ICU trial is approved by the Danish Health and
Medicine Agency (2015030166), the Committees on
Health Research Ethics in the Capital Region of Denmark
(H-15003141), the Danish Data Protection Agency
(RH-2015-3203695), and by all respective national regula-
tory bodies in the participating countries, and was regis-
tered at clinicaltrials.gov (no. NCT02467621) [22].
Population
The SUP-ICU trial [22] will include critically ill adult
patients acutely admitted to one of the participating ICUs
with one or more of the following risk factors for gastro-
intestinal bleeding:
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1. Shock (continuous infusion of vasopressors or
inotropes, systolic blood pressure < 90 mmHg, mean
arterial blood pressure < 70 mmHg or plasma lactate
level of ≥ 4 mmol/l)
2. Need for intermittent or continuous RRT
3. Use of invasive mechanical ventilation expected to
last more than 24 hours
4. Acute (within previous 24 hours) coagulopathy or
history of coagulopathy (platelet count < 50 × 109/l
or international normalized ratio > 1.5 or
prothrombin time > 20 s within the 6 months prior
to hospital admission)
5. Ongoing treatment with any anticoagulant
(prophylactic doses excluded)
6. History of chronic liver disease (portal hypertension,
cirrhosis proven by biopsy, computed tomography
scan, or ultrasound or history of variceal bleeding or
hepatic encephalopathy)
Exclusion criteria include contraindications to proton
pump inhibitors, current daily use of any proton pump
inhibitor or any histamine-2-receptor antagonist,
gastrointestinal bleeding of any origin during current
hospital admission, diagnosis of peptic ulcer during
current hospital admission, organ transplant during
current hospital admission, withdrawal from active
therapy or brain death, fertile woman with positive
test for urinary or plasma human chorionic gonado-
tropin, and patients in whom consent according to
national regulations cannot be obtained [22]. In
SIREN the population of interest is patients with
acute kidney injury receiving RRT.
Exposure
A)RRT within 3 days: All patients receiving RRT at
time of randomization, and patients needing RRT
within the first 72 hours following randomization.
B) RRT after 3 days: All patients requiring RRT after
72 hours following randomization.
Comparator
No RRT: All patients without need of RRT at time of
randomization. If a patient subsequently receives RRT
she or he will be moved from the “no RRT” group to the
“RRT within 3 days” group if the first RRT session
occurs within 72 hours and the “RRT after 3 days” group
if the first RRT session occurs after 72 hours.
DOIREPYDUTS
Enrolment Allocation Post-allocation Close-out 
TIMEPOINT t0 t0 D1 D2 D3 D4 
Daily  
until ICU 
discharge 
(max. D90, 
or death) 
D365
ENROLMENT in the 
SUP-ICU trial:
Eligibility screen 
(SUP-ICU) X  
Informed consent X  
Baseline clinical 
data/ demographics X  
Allocation (SUP-ICU)  X 
INTERVENTIONS (in 
SUP-ICU trial):
[Pantoprazole or 
placebo, daily]
SIREN outcome 
measures:
[data on RRT need **] X  X X X X X 
[data on secondary 
outcomes]
X  X X X X X  
[data on disease 
severity] X  X X X X X  
[data on transfusion 
requirements, 
interventions to stop 
GI bleeding]
  X X X X X  
[analysis  of mortality 
data from SUP-ICU 
trial]
      X X 
Fig. 1 SIREN (pre-planned sub-analysis of the SUP-ICU trial) data * * Detailed information on SUP-ICU trial assessments is provided in [22].
** RRT = Renal replacement therapy
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Outcome measures in SIREN
Primary outcome measure
Proportion of patients with clinically important gastro-
intestinal bleeding (as defined in the next section).
Secondary outcome measures
1. Proportion of patients with one or more of the
following adverse events: clinically important
gastrointestinal bleeding, pneumonia, C. difficile
infection, or acute myocardial ischemia in the ICU
2. Proportion of patients with serious adverse reactions
3. Proportion of patients with one or more infectious
adverse events (pneumonia or C. difficile infection)
in the ICU
4. Days alive without use of mechanical ventilation,
RRT, or circulatory support in the 90 day period
5. 90 day mortality post-randomization (if available,
1 year mortality, i.e. 365 days)
6. Proportion of patients receiving treatment
(interventions) to stop gastrointestinal bleeding (i.e.
endoscopy, open or laparoscopic surgery, or coiling)
7. Number of units of packed red blood cells
transfused
Definitions
Clinically important gastrointestinal bleeding
Clinical observation of hematemesis, coffee ground emesis,
melena, hematochezia, or bloody nasogastric aspirate and
fulfillment of one or more of the following criteria:
 Spontaneous drop in systolic blood pressure, mean
arterial pressure or diastolic pressure of 20 mmHg
or more within 24 hours after the gastrointestinal
bleeding episode, in the absence of other causes
 Vasopressor (i.e. norepinephrine, epinephrine,
dopamine, vasopressin, or terlipressin) initiated or
increased by 20% or more within 24 hours after the
gastrointestinal bleeding episode, in the absence of
other causes
 Hemoglobin decrease by at least 2 g/dl (1.24 mmol/
l) within 24 hours after the gastrointestinal bleeding
episode, in the absence of other causes
 Transfusion of two or more units of packed red
blood cells within 24 hours after the gastrointestinal
bleeding episode, in the absence of other causes
Data collection and management
Prospectively collected data will be entered in the SUP-
ICU database via electronic case report files. Web-based
access to the database is provided to researchers on a 24/7
basis. Data will be encoded by using a unique patient iden-
tification number. Data will be handled according to the
requirements of local data protection authorities or
respective ethical committees. All trial data will be stored
in a protected environment for a minimum of 15 years
and anonymized if requested by the authorities.
The following data will be collected in SIREN: age, sex,
comorbidities including previous or chronic RRT, date of
hospital and ICU admission, renal Sepsis-related Organ
Failure Assessment (SOFA) score, total SOFA score,
Simplified Acute Physiology Score (SAPS) II, date of ICU
discharge, use of RRT at baseline, use of RRT within the
first 3 days of ICU admission, use of RRT after 3 days
following randomization, data on clinically important
gastrointestinal bleeding episodes, including confirmation
of bleeding and interventions to stop bleeding, number of
transfused red blood cell units, use of non-steroidal anti-
phlogistic or anti-inflammatory drugs at hospital admis-
sion, use of anticoagulants at hospital admission, lowest
platelet count within 24 hours prior to randomization,
and the outcome measures listed previously. Further
details are available elsewhere [21].
Safety
Patients can be withdrawn from the SUP-ICU trial in
the case of clinical indication for use of proton pump
inhibitors or histamine-2-receptor antagonists, clinical
indication for withdrawal as judged by a responsible
clinician or local investigator, in the case of a request for
withdrawal by the patient or patient’s next of kin, and in
the case of serious adverse reaction or suspected
unexpected serious adverse reaction [22]. Details of
serious adverse reactions and suspected unexpected
serious adverse reactions are given elsewhere [22].
Statistical analysis
SIREN data analysis will be performed by the SIREN
study team after closure of the main database and
according to the statistical analysis plan outlined next.
We will use R (R-project.org) for the analysis.
Missing data
In the case of missing observations of > 5% in any specific
analysis, that analysis will be performed both as complete-
case and using multiple imputation based on chained
equations. All variables in the specific analysis will be
included in the multiple imputation, as well as stratifica-
tion variables (site and presence of hematological cancer),
age, SOFA score at baseline, type of admission (medical,
elective surgery, or emergency surgery), SAPS II score at
baseline, RRT at baseline, mechanical ventilation at base-
line, shock at baseline, proportion of patients with
clinically important gastrointestinal bleeding, proportion
of patients with one or more episodes of serious adverse
events (pneumonia, C. difficile infection, or myocardial is-
chemia), and 90 day mortality. If multiple imputation is
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used, the primary result of the trial will be based on these
data. For additional details on the handling of missing data
in SUP-ICU, please refer elsewhere [21].
Primary analysis
The primary analysis will be a conventional subgroup
analysis of the effects of pantoprazole versus placebo in
patients with RRT at baseline (i.e. at randomization). We
will use Cox models censoring at death or loss to follow-
up and intention to treat in the two groups defined by
RRT at baseline. We will include the interaction between
baseline RRT and allocated treatment, which will constitute
the main test of differences in effects. Statistical signifi-
cance will be considered for P < 0.1; whether we find a
statistically significant difference or not, we will report
hazard ratios stratified by baseline RRT. As treatment is
randomized, we will not control the analysis for any other
variables than stratification variables (i.e. site and presence
of hematological malignancy at randomization). Secondary
outcome measures will be analyzed in a similar manner as
the primary outcome measure when they can be expressed
as time-to-event outcome measures (no. 4). Secondary
outcome measures nos. 1–3, 5, and 6 will be analyzed
using logistic regression and secondary outcome measure
no. 7 will be analyzed using Poisson regression. All regres-
sions will include the same covariates as the primary
analysis.
Analysis of the effect of RRT
For the analysis of the effects of RRT itself, the outcome
measures will be compared between the dynamically up-
dated groups (“No RRT”, “RRT within 72 hours”, “RRT
after 72 hours”) using Cox models with delayed entry. This
is comparable to a Cox model with time-varying exposure,
where the time-varying exposure is the dynamic group for
each patient. We will adjust the analysis for the following
important confounders: the investigational medicinal
product (pantoprazole vs. placebo), disease severity (SAPS)
II at baseline, anticoagulation at hospital admission, age,
and sex. In addition, raw rates will be reported for each
day of the first week of ICU admission. In the analysis of
RRT itself, we will only consider time to gastrointestinal
bleeding.
Power analysis
The sample size of SIREN is fixed. The SUP-ICU trial
includes 3350 ICU patients (total cohort). We expect that
335 patients (i.e. 10%) present with acute kidney injury
requiring RRT at baseline. The actual power of the
primary analysis will be expressed through the width of
the confidence intervals for effect parameters, which will
be included in the SIREN manuscript.
Timeline
2015: Development of research strategy and SIREN study
protocol
2016–2017: Inclusion of patients to SUP-ICU
2018: SUP-ICU and SIREN data analysis, writing, and
submission of manuscript
Publication/authorships
A manuscript will be submitted to a peer-reviewed journal
following publication of the SUP-ICU trial main results
whether positive, negative, or neutral. Publication of SIREN
will be performed concomitant to the analysis of the SUP-
ICU, with a manuscript drafted within 180 days of comple-
tion of the statistical analysis. SIREN will reference the
main publication as well as refer to and put respective
main primary and secondary outcome measures or results
into perspective. A SIREN scientific committee will be
formed, which is chaired by the SIREN principal investiga-
tor (the first author of this manuscript). Authors of the
SUP-ICU trial, national principal investigators, or trial site
investigators will be invited as co-authors, depending on
their respective personal input. The SIREN scientific com-
mittee will decide on which journal is deemed appropriate,
and will grant authorships depending on personal input
according to the Vancouver definitions [24].
Discussion
Trial rationale
The evidence is sparse [4], but use of stress ulcer prophy-
laxis is recommended in adult critically ill patients with risk
factors for gastrointestinal bleeding, and three out of four
ICU patients receive acid suppressants [3]. From a clinical
perspective, critically ill patients with acute kidney injury
requiring RRT constitute a high-risk group. In the outlined
study, we aim to assess the balance between the benefits
and harms of prophylactic proton pump inhibitors (specif-
ically, pantoprazole) in the subgroup of patients with acute
kidney injury requiring RRT. We will compare patients
with and without need of baseline RRT (primary analysis),
and assess the impact of developing acute kidney injury
with need of RRT during ICU stay (secondary analysis).
We will exclusively assess patient-important outcome
measures, including clinically important gastrointestinal
bleeding, nosocomial infections, and mortality. SIREN is
expected to provide contemporary and important data on
the risk of gastrointestinal bleeding in critically ill patients
undergoing RRT, including guidance on use of acid
suppressants in this population. This has important impli-
cations for patients and relatives, the health care system,
and society.
Strengths and limitations
Using data from a large international pragmatic high-
quality randomized clinical trial will result in high external
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validity (generalizability). The extent of missing data is
expected to be low, and missing data will be handled as
recommended [25]. Analysis will be conducted according
to the present predefined statistical analysis plan. This
protocol has been prepared according to the STROBE
statement [23] (Additional file 1). Results are applicable to
daily clinical practice with potential direct impact on stress
ulcer prophylaxis prescription practice on the ICU.
The limitations include the fixed sample size with risk of
inflated estimates (type 1 error). Moreover, only the total
cohort of ICU patients with need for RRT will be analyzed,
and we will not be able to conclude on potential effects of
specific RRT modalities (e.g. intermittent vs. continuous
RRT), timing, or any specific mode of anticoagulation used
in the context of RRT, or applied RRT dose [18, 26, 27].
In conclusion, the balance between the benefits and
harms of prophylactic proton pump inhibitors in acutely
ill adult ICU patients with acute kidney injury requiring
RRT is unknown. SIREN aims to provide important
high-quality data on this topic.
Trial status
The SUP-ICU trial is currently actively recruiting patients.
A total of 3023 patients were randomized as of August 22,
2017. Completion of patient recruitment is expected for
November 2017.
Additional files
Additional file 1: STROBE statement. (DOC 85 kb)
Additional file 2: SPIRIT 2013 checklist. (DOC 121 kb)
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